Zafgen Inc. Daily Stock Analysis

Daily Stock Analysis, ZFGN, Zafgen Inc, priceseries

Zafgen Inc. Daily Stock Analysis
Stock Information
Open
12.24
Close
11.88
High
14.88
Low
11.40
Previous Close
13.92
Daily Price Gain
-2.04
YTD High
55.36
YTD High Date
Mar 20, 2015
YTD Low
0.62
YTD Low Date
Mar 19, 2020
YTD Price Change
-7.87
YTD Gain
-39.85%
52 Week High
55.36
52 Week High Date
Mar 20, 2015
52 Week Low
0.62
52 Week Low Date
Mar 19, 2020
52 Week Price Change
-7.87
52 Week Gain
-39.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2017
3.33
Jan 20. 2017
3.81
11 Trading Days
14.41%
Link
LONG
Mar 17. 2017
4.34
Apr 10. 2017
4.84
16 Trading Days
11.45%
Link
LONG
Dec 20. 2017
3.95
Jan 29. 2018
5.77
25 Trading Days
46.08%
Link
LONG
Mar 6. 2018
8.26
Mar 7. 2018
9.13
1 Trading Days
10.53%
Link
LONG
May 30. 2018
7.16
May 31. 2018
7.53
1 Trading Days
5.23%
Link
LONG
Jun 27. 2018
8.50
Jul 13. 2018
9.71
11 Trading Days
14.25%
Link
LONG
Dec 23. 2019
0.94
Jan 2. 2020
1.02
6 Trading Days
8.24%
Link
LONG
Jan 7. 2020
1.26
Jan 9. 2020
1.48
2 Trading Days
17.06%
Link
Company Information
Stock Symbol
ZFGN
Exchange
NasdaqGS
Company URL
http://www.zafgen.com
Company Phone
617-622-4003
CEO
Thomas E. Hughes
Headquarters
Massachusetts
Business Address
175 PORTLAND STREET, 4TH FLOOR, BOSTON, MA 02114
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001374690
About

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways. Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi Syndrome, or PW craniopharyngioma-associated obesity. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Description

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company's lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading